Creative Biolabs is helping researchers overcome challenges of gene therapy research by providing analytical testing ...
Adeno Associated Virus Vector Manufacturing Market · GlobeNewswire Inc. Dublin, Jan. 26, 2026 (GLOBE NEWSWIRE) -- The "Adeno Associated Virus Vector Manufacturing Market - Global Industry Size, Share, ...
A new study characterizes a bioengineered adeno-associated virus (AAV)3B capsid variant that demonstrates improved transduction to human liver cells. Another advantage of the AAV3B-V04 capsid was its ...
The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.
DUBLIN--(BUSINESS WIRE)--The "Adeno Associated Virus Vector Manufacturing Market Size, Share & Trends Analysis Report By Scale Of Operations (Clinical, Commercial), By Method, By Application, By ...
Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the new kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately ...
With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor ...
For the most part, viral vector–based gene therapies have been used against rare diseases. But now these gene therapies are also starting to be used against diseases that have larger patient ...
Recent clinical trials utilizing high doses of adeno-associated virus (AAV) vectors have highlighted a new challenge to AAV gene transfer—activation of the complement system. A new article in Human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results